OraSure Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

OraSure Technologies şirketinin toplam hissedar öz sermayesi $425.6M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $464.1M ve $38.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$278.57m
Eşitlik	US$425.57m
Toplam yükümlülükler	US$38.52m
Toplam varlıklar	US$464.09m

Son finansal sağlık güncellemeleri

We're Not Very Worried About OraSure Technologies' (NASDAQ:OSUR) Cash Burn Rate

Jan 16

Is OraSure Technologies (NASDAQ:OSUR) In A Good Position To Invest In Growth?

Aug 11

Recent updates

Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results

Nov 08

OraSure: An NCAV Diamond In The COVID Rough

Nov 04

OraSure Technologies: Nursing A COVID-19 Hangover

Sep 10

OraSure Technologies, Inc. (NASDAQ:OSUR) Just Reported Earnings, And Analysts Cut Their Target Price

May 11

Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S

Apr 17

Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Mar 01

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

Feb 29

OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry

Dec 20

Returns On Capital At OraSure Technologies (NASDAQ:OSUR) Have Stalled

Nov 08

Industry Analysts Just Upgraded Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Forecasts By 14%

Aug 09

Analysts Have Just Cut Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Estimates By 12%

May 16

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

May 13

Party Time: Brokers Just Made Major Increases To Their OraSure Technologies, Inc. (NASDAQ:OSUR) Earnings Forecasts

Feb 17

Are OraSure Technologies, Inc. (NASDAQ:OSUR) Investors Paying Above The Intrinsic Value?

Jun 14

OraSure: Not So Sure With Softening Fundamentals, Fairly Priced At $2.54

Jun 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: OSUR 'nin kısa vadeli varlıkları ( $350.2M ) kısa vadeli yükümlülüklerini ( $27.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: OSUR şirketinin kısa vadeli varlıkları ( $350.2M ) uzun vadeli yükümlülüklerini ( $10.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: OSUR borçsuzdur.

Borcun Azaltılması: OSUR son 5 yıldır borcu bulunmamaktadır.

Borç Kapsamı: OSUR un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: OSUR şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

OraSure Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Not Very Worried About OraSure Technologies' (NASDAQ:OSUR) Cash Burn Rate

Is OraSure Technologies (NASDAQ:OSUR) In A Good Position To Invest In Growth?

Recent updates

Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results

OraSure Technologies, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

New minor risk - Profit margin trend

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

OraSure: An NCAV Diamond In The COVID Rough

OraSure Technologies, Inc. to Report Q3, 2024 Results on Nov 06, 2024

OraSure Technologies, Inc. Appoints John P. Kenny as New Member of the Board, Member of the Nominating and Corporate Governance Committee

OraSure Technologies: Nursing A COVID-19 Hangover

Consensus EPS estimates upgraded to US$0.098 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2024

OraSure Technologies, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Price target decreased by 7.5% to US$6.13

Consensus EPS estimates fall by 54%

Price target decreased by 7.9% to US$6.95

OraSure Technologies, Inc. (NASDAQ:OSUR) Just Reported Earnings, And Analysts Cut Their Target Price

New minor risk - Shareholder dilution

OraSure Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S

New minor risk - Shareholder dilution

OraSure Technologies, Inc., Annual General Meeting, May 14, 2024

Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

New minor risk - Earnings quality

OraSure Technologies, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

Full year 2023 earnings: EPS exceeds analyst expectations

OraSure Technologies, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Chief Product Officer notifies of intention to sell stock

OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Provides Financial Guidance for the Fourth Quarter 2023

Returns On Capital At OraSure Technologies (NASDAQ:OSUR) Have Stalled

OraSure Technologies, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment improves as stock rises 41%

Industry Analysts Just Upgraded Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Forecasts By 14%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2023

OraSure Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

OraSure Technologies, Inc. Announces Election of Robert W. McMahon to its Board of Directors, Effective July 31, 2023

Price target decreased by 7.2% to US$6.45

OraSure Technologies, Inc. Announces Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access

Investor sentiment improves as stock rises 17%

Chief Financial Officer recently bought US$493k worth of stock

Investor sentiment deteriorates as stock falls 22%

Analysts Have Just Cut Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Estimates By 12%

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

Price target increased by 13% to US$6.95

Orasure Technologies, Inc. Provides Earnings Guidance for the Second Quarter 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. to Report Q1, 2023 Results on May 10, 2023

Party Time: Brokers Just Made Major Increases To Their OraSure Technologies, Inc. (NASDAQ:OSUR) Earnings Forecasts

Price target increased by 8.0% to US$5.88

Full year 2022 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Provides Revenue Guidance for the First Quarter of 2023

OraSure Technologies, Inc. to Report Q4, 2022 Results on Feb 14, 2023

We're Not Very Worried About OraSure Technologies' (NASDAQ:OSUR) Cash Burn Rate

Consensus estimates of losses per share improve by 69%

High number of new directors

OraSure Technologies, Inc. Announces Executive Changes

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Reports Goodwill and Long-Lived Assets Impairment Charges for the Third Quarter Ended September 30, 2022

Orasure Technologies Receives General Clearance for Its ORAcollect--Dx Device for over the Counter Use from the U.S. Food and Drug Administration

OraSure Technologies, Inc. Announces InteliSwab Covid-19 Rapid Test Now Available in Amazon’s Online Store

OraSure Technologies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

OraSure wins $8.6M government contract for next-gen Ebola test

OraSure: Revenue Mix Continues To Present Risk

Independent Director recently bought US$200k worth of stock

Biden administration ending free at-home COVID tests due to lack of funding

Independent Chairman of the Board recently bought US$54k worth of stock

Consensus revenue estimates increase by 11%